About Tirzepatide
Human randomized trials · Controlled study formulation
What it is studied for
A dual GIP/GLP-1 receptor agonist studied in glucose regulation and body-weight research.
What selected research found
SURPASS-1 reported improved glycemic control versus placebo in type 2 diabetes. SURMOUNT-1 reported greater body-weight reduction versus placebo. Gastrointestinal adverse events occurred.
Evidence limits
These findings concern clinical study formulations and monitored participants. They do not establish equivalence or human-use suitability of this laboratory material.
Selected sources
References reviewed October 10, 2026.
Research use only. These notes summarize selected publications; they are not a systematic review, medical advice, dosing instructions, or evidence about this product lot. Clinical studies used controlled study formulations and supervision. AuraBio materials are not for human or veterinary use. Review the exact material identity and available lot documentation for your laboratory application.






Reviews
There are no reviews yet.